MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency

Phase 2
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Alpha-1 Antitrypsin Deficiency
Emphysema
Interventions
Drug: Aspirin
Drug: Placebo
Other: Withdrawal from alpha1 antitrypsin replacement therapy
First Posted Date
2017-01-04
Last Posted Date
2021-02-17
Lead Sponsor
Columbia University
Target Recruit Count
15
Registration Number
NCT03008915
Locations
🇺🇸

Columbia University, New York, New York, United States

The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV

Phase 2
Completed
Conditions
Polycythemia Vera
Interventions
Procedure: Phlebotomies
Drug: AOP2014
Drug: ASA
First Posted Date
2016-12-28
Last Posted Date
2023-08-03
Lead Sponsor
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Target Recruit Count
127
Registration Number
NCT03003325
Locations
🇮🇹

Divisione Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy

🇮🇹

UOC Ematologia, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Messina, Sicilia, Italy

🇮🇹

Divisione Ematologia Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" Palermo, Palermo, Sicilia, Italy

and more 20 locations

NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH

Phase 2
Completed
Conditions
Atrial Fibrillation
Intracerebral Hemorrhage
Interventions
First Posted Date
2016-12-21
Last Posted Date
2020-03-20
Lead Sponsor
Population Health Research Institute
Target Recruit Count
30
Registration Number
NCT02998905
Locations
🇨🇦

Foothills Medical Centre, Calgary, Alberta, Canada

🇨🇦

University of Alberta Hospital, Edmonton, Alberta, Canada

🇨🇦

Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada

and more 6 locations

The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss

Phase 4
Conditions
Recurrent Pregnancy Loss
Interventions
First Posted Date
2016-12-13
Last Posted Date
2017-03-08
Lead Sponsor
Shanghai First Maternity and Infant Hospital
Target Recruit Count
500
Registration Number
NCT02990403
Locations
🇨🇳

Shanghai first Maternity and Infant health hospital, Tong Ji University, Shanghai, China

Diagnosis and Treatment Strategy of Recurrent Spontaneous Abortion Associated With Thrombophilla

Phase 4
Conditions
Thrombophilia With Recurrent Pregnancy Loss
Interventions
First Posted Date
2016-12-08
Last Posted Date
2016-12-09
Lead Sponsor
Shanghai First Maternity and Infant Hospital
Target Recruit Count
600
Registration Number
NCT02986594
Locations
🇨🇳

Shanghai first Maternity and Infant health hospital, Tong Ji University, Shanghai, China

Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease

Phase 4
Completed
Conditions
Atrial Fibrillation
Valve Heart Disease
Interventions
First Posted Date
2016-12-06
Last Posted Date
2021-01-13
Lead Sponsor
Asan Medical Center
Target Recruit Count
120
Registration Number
NCT02982850
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

PREVENTion of Clot in Orthopaedic Trauma

Phase 3
Completed
Conditions
Blood Clot
Trauma
Interventions
Drug: Low Molecular Weight Heparin (LMWH)
Drug: Acetylsalicylic acid
First Posted Date
2016-12-06
Last Posted Date
2024-05-14
Lead Sponsor
Major Extremity Trauma Research Consortium
Target Recruit Count
12424
Registration Number
NCT02984384
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

University of Arizona, Tucson, Arizona, United States

🇺🇸

MetroHealth Medical Center, Cleveland, Ohio, United States

and more 18 locations

Rivaroxaban or Aspirin for Biological Aortic Prosthesis

Phase 4
Conditions
Thrombosis
Aortic Stenosis
Aortic Regurgitation
Interventions
First Posted Date
2016-11-29
Last Posted Date
2018-06-27
Lead Sponsor
Christian Torp-Pedersen
Target Recruit Count
1000
Registration Number
NCT02974920
Locations
🇩🇰

Aalborg University Hospital, Aalborg, Denmark

🇩🇰

Odense University Hospital, Odense, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

and more 1 locations

Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study

Not Applicable
Conditions
Ischemic Attack, Transient
Stroke, Acute
Interventions
Drug: Sanchitongshu
Drug: placebo of Sanchitongshu
Drug: Aspirin
Drug: placebo of clopidogrel
Drug: Clopidogrel
First Posted Date
2016-11-29
Last Posted Date
2016-11-29
Lead Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
120
Registration Number
NCT02975076

PPARGC1β and CNTN4 Genotype Aspirin Study

Phase 4
Conditions
Cardiovascular Diseases
Interventions
First Posted Date
2016-11-22
Last Posted Date
2016-11-22
Lead Sponsor
Royal College of Surgeons, Ireland
Target Recruit Count
160
Registration Number
NCT02970604
Locations
🇮🇪

Royal College of Surgeons in Ireland, Dublin, Ireland

© Copyright 2025. All Rights Reserved by MedPath